Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Sep 24, 2026
Bitwise Hyperliquid ETF (BHYP) Posts +14% Gains Over 30 Days

Bitwise Hyperliquid ETF (BHYP) Posts +14% Gains Over 30 Days

Key Takeaways

  • BHYP has advanced roughly 14% over the past 30 days, extending a broader gain of more than 50% over the trailing three months.
  • The fund provides 100% spot exposure to HYPE, the native token of the Hyperliquid on-chain derivatives exchange, so its returns track HYPE's price directly.
  • Primary drivers include Hyperliquid's revenue-linked token buybacks, in-house staking rewards, and growing institutional demand for regulated crypto exposure.
  • Price action has been volatile rather than smooth, with sharp multi-day surges punctuated by notable pullbacks.

Understanding the Bitwise Hyperliquid ETF (BHYP) and Its Exposure

The BHYP is an exchange-traded product designed to deliver exposure to the value of Hyperliquid held in the trust, after operating expenses. A secondary goal is to generate additional Hyperliquid through staking. Unlike diversified equity or bond funds, BHYP holds only the HYPE token, resulting in a 100% allocation to this single digital asset and a direct link to its market price.

Structured as a Delaware statutory trust listed on NYSE Arca, the fund is not registered under the Investment Company Act of 1940 and therefore does not offer the same investor protections as traditional ETFs or mutual funds. It carries a 0.34% sponsor fee, which Bitwise waived for the first month on the initial $500 million in assets. A notable feature is in-house staking via Bitwise Onchain Solutions, with rewards passed to investors after a service fee—this adds a modest yield component on top of pure price exposure.

Hyperliquid operates as a Layer 1 blockchain built for on-chain perpetual futures. The platform handled roughly $2.9 trillion in trading volume in 2025, representing more than 400% growth year over year, and holds about 60% of global on-chain derivatives open interest. Nearly 99% of protocol revenue flows through its Assistance Fund to repurchase HYPE, creating a built-in buyback mechanism that connects token demand directly to trading activity.

Recent Price Performance: +14% Over 30 Days and +54% Quarterly

Over the last 30 days, BHYP rose from roughly $46 per share to about $52.65, for a gain of approximately 14%. The advance was uneven, with consolidation near $44 in mid-September followed by a rapid multi-session surge above $52 toward the end of the period. I also checked this using Tickeron’s AI Screener to see how the fund compares to other thematic crypto products on momentum metrics.

The quarterly trend has been even stronger. Roughly three months ago, the fund traded near $34, so the current level reflects an advance of about 54%. This movement has been trend-driven yet marked by high volatility, typical of a single-asset crypto-linked product rather than a diversified portfolio. The overall pattern shows pronounced directional momentum interrupted by sharp corrections.

Key Drivers Behind the 30-Day Move

Because BHYP holds only HYPE, its recent performance stems almost entirely from the token’s price appreciation. Hyperliquid’s tokenomics, which direct the vast majority of protocol revenue toward open-market HYPE repurchases, create ongoing demand that strengthens when derivatives trading volumes increase. The platform’s continued leadership in on-chain perpetuals open interest supports this dynamic.

Institutional interest has played a role as well. As one of the first U.S.-listed Hyperliquid products, BHYP has drawn inflows from investors seeking regulated, exchange-traded exposure without managing wallets or private keys. Bitwise’s commitment to direct 10% of the fund’s management fee toward purchasing and holding HYPE on its balance sheet provides another structural source of demand. Staking rewards, earned through the fund’s in-house infrastructure and automatically reinvested, further bolster the case. Broader digital-asset sentiment likely amplified these factors when risk appetite favored alternative Layer 1 tokens and DeFi themes.

Factors Supporting the Quarterly Advance

The roughly 54% gain over the trailing quarter reflects a combination of structural and cyclical elements. Since its launch in mid-May 2026, BHYP has benefited from early institutional demand in a new category of spot crypto ETFs, with issuers competing to offer Hyperliquid exposure. This accumulation phase has aligned with appreciation in the underlying token.

On the fundamentals, Hyperliquid’s rapid growth in trading volume and its revenue-to-buyback model have strengthened the investment case for HYPE over several months. The platform’s dominant share of on-chain derivatives open interest positions it to benefit from increased activity in perpetual futures markets. These elements, together with firmer risk sentiment across digital assets, have supported the fund’s broader quarterly momentum.

Outlook: What to Watch for BHYP Investors

The main variable going forward is HYPE’s price, which remains sensitive to crypto market sentiment and activity on the Hyperliquid platform. Monitoring protocol trading volume and the pace of token repurchases will be important, as these directly affect the buyback-driven demand supporting the token. Staking yield, which varies with protocol revenue, is another metric worth tracking.

Competitive and regulatory developments also merit attention. Other Hyperliquid products from competing issuers could influence BHYP’s inflows and market share, while changes in U.S. crypto regulation or broader monetary policy—especially shifts in interest-rate expectations and risk appetite—are likely to shape demand for digital-asset ETFs in general. Given the fund’s single-asset concentration and its status as a non-1940 Act ETP, investors should consider concentration, volatility, and structural risks alongside the growth thesis. These themes will likely shape BHYP’s path in the months ahead.

Using Tickeron’s AI Tools in My Research

When evaluating products like BHYP, I often turn to Tickeron’s AI-powered platforms to scan for comparable ETFs and tokens based on momentum, volatility, and performance patterns. These tools help surface relevant data points quickly and support a more structured approach to thematic exposure analysis. Explore the AI Screener to see how it can fit into your own workflow.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BHYP

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


Industry description

The investment seeks to provide exposure to the value of Hyperliquid held by the Trust, less the expenses of the Trust’s operations; to derive additional Hyperliquid through staking is secondary consideration. The Trust will hold Hyperliquid and establish its net asset value (“NAV”) by reference to the CF Hyperliquid-Dollar U.S. Settlement Price (“Pricing Benchmark”).
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Digitalcurrency

Category
Digital Assets
Address
us
Phone
N/A
Web
N/A
Interact to see
Advertisement
Kingsoft Cloud Holdings Limited (KC) shares plunged about 9% in the most recent session, extending a sharp pullback after a recent rally. The selloff reflects mounting concerns around profitability, with the company still loss-making and showing weak multi-year revenue growth.
BAK shares fell roughly 11% in the latest trading session, marking a sharp single-day drop for the Brazilian petrochemical producer The decline comes amid persistent concerns about high leverage, a weaker credit profile, and soft petrochemical margins in a challenging macro environment for chemicals​
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.